jp85yzz

Property	Value
?:abstract	BACKGROUND: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. METHODS: This retrospective multicentric cohort study used the Programme de Médicalisation des Systèmes d\'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts. FINDINGS: Eighty-nine patients were included. The median age was 67 years (range, 19–92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62–81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2·87, 1·20–6·85, p = 0·02) and relapsed/refractory lymphoma (hazard ratio 2·54, 1·14–5·66, p = 0·02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3·20, 1·33–7·72, p = 0·01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%). INTERPRETATION: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population. FUNDING: There have been no specific funds to run this study.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/9jp85yzz_hasAnnotation_C0024299> <https://research.tib.eu/covid-19/entity/9jp85yzz_hasAnnotation_C0079731> <https://research.tib.eu/covid-19/entity/9jp85yzz_hasAnnotation_C3541329> <https://research.tib.eu/covid-19/entity/9jp85yzz_hasAnnotation_C4525060>
?:creator	<https://research.tib.eu/covid-19/entity/Lamure%2C_Sylvain%3B_Dul%C3%A9ry%2C_R%C3%A9my%3B_Di_Blasi%2C_Roberta%3B_Chauchet%2C_Adrien%3B_Laureana%2C_C%C3%A9cile%3B_Deau-Fischer%2C_B%C3%A9n%C3%A9dicte%3B_Drenou%2C_Bernard%3B_Soussain%2C_Carole%3B_Rossi%2C_C%C3%A9dric%3B_No%C3%ABl%2C_Nicolas%3B_Choquet%2C_Sylvain%3B_Bologna%2C_Serge%3B_Joly%2C_Bertrand%3B_Kohn%2C_Milena%3B_Malak%2C_Sandra%3B_Fouquet%2C_Guillemette%3B_Daguindau%2C_Etienne%3B_Bernard%2C_Sophie%3B_Thi%C3%A9blemont%2C_Catherine%3B_Cartron%2C_Guillaume%3B_Lacombe%2C_Karine%3B_Besson%2C_Caroline>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.eclinm.2020.100549>
?:doi	10.1016/j.eclinm.2020.100549
?:journal	EClinicalMedicine
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/37f581ab7f98d57aa772f5b48b61c5e2a042431b.json
?:pmc_json_files	document_parses/pmc_json/PMC7550257.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7550257>
?:pmid	<https://research.tib.eu/covid-19/entity/33073216.0>
?:pmid	33073216.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/9jp85yzz_HAS_C5203670_COEXISTS_WITH_C1856053>
?:sha_id	<https://research.tib.eu/covid-19/entity/37f581ab7f98d57aa772f5b48b61c5e2a042431b>
?:source	Elsevier; Medline; PMC
?:title	Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-13

Property

Value

?:abstract

BACKGROUND: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality. METHODS: This retrospective multicentric cohort study used the Programme de Médicalisation des Systèmes d\'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts. FINDINGS: Eighty-nine patients were included. The median age was 67 years (range, 19–92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62–81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2·87, 1·20–6·85, p = 0·02) and relapsed/refractory lymphoma (hazard ratio 2·54, 1·14–5·66, p = 0·02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3·20, 1·33–7·72, p = 0·01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%). INTERPRETATION: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population. FUNDING: There have been no specific funds to run this study.

is ?:annotates of